Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerDavid D.L. Bowtell, Frances R. Balkwill, Steffen Böhm et al.|Nature reviews. Cancer|2015Cited by 1.4k
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R. Clamp, Jonathan A. Ledermann, Elizabeth C James et al.|The Lancet|2019Cited by 223
Performance status score: do patients and their oncologists agree?Sarah P. Blagden, David Gilligan, Susan C. Charman et al.|British Journal of Cancer|2003Cited by 222
La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAsRoni M. Lahr, Andrea J. Berman, Bruno D. Fonseca et al.|eLife|2017Cited by 201
Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid MalignanciesDavid Olmos, Sarah P. Blagden, Douglas S. Barker et al.|Clinical Cancer Research|2011Cited by 168